Outcomes with trilaciclib versus granulocyte colony stimulating factor regarding chemotherapy-associated adverse events, dose reductions, and subsequent therapies in small cell lung cancer.
Authors: Weston He, Ahmad Karkash, Paresh Kumar, Yan Han, Justin Wang Shi, Julian A. Marin-Acevedo, Mya Tran, Misty Dawn Shields